Product Reports Resources Pricing Login Book a demo

Element Biosciences

Biotech & Life Sciences · San Diego, United States · Founded 2017

Element Biosciences is a biotechnology startup that specializes in next-generation sequencing (NGS) technology. The company's primary product is the AVITI System, a compact benchtop design that offers high-quality sequencing at a low cost. This system is designed to meet the needs of end users by delivering industry-leading accuracy at low run costs, enabling users to do more with their resources. Element Biosciences operates in the biotechnology market, serving clients in various fields that require DNA sequencing. These clients could range from academic researchers to pharmaceutical companies. The company's business model revolves around the sale of its AVITI System and the provision of sequencing services. The AVITI System is designed to be cost-effective, charging only $1 per million reads, which is significantly lower than the industry average. The company has also established partnerships with other firms in the biotech industry, such as QIAGEN, to offer complete NGS workflows for the AVITI System. This partnership allows Element Biosciences to provide a comprehensive solution for its clients' sequencing needs. Element Biosciences also offers a grant program, the 2023 AVITI for All Grant, which provides free sequencing for any application in any field. This initiative not only accelerates research but also showcases the capabilities of the AVITI System. In summary, Element Biosciences is a biotech startup that offers affordable and high-quality sequencing solutions. The company's innovative technology and strategic partnerships position it well in the competitive biotech market. Keywords: Biotechnology, Next-Generation Sequencing, AVITI System, Low-Cost Sequencing, High-Quality Sequencing, Biotech Market, Sequencing Services, Strategic Partnerships, Grant Program, DNA Sequencing.

Investors

14 investors on Element Biosciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 6 investors entered at this stage
Series B+ 8 investors entered at this stage

Global footprint

Where Element Biosciences has talent and traffic

Workforce by country
13 countries with
team presence
🇺🇸 United States88.6%
🇩🇪 Germany2.6%
🇳🇱 Netherlands2.3%
🇬🇧 United Kingdom1.5%
🇫🇷 France1.5%
Top 5 of 13 shown
Web traffic by country
26K monthly visits
across markets
🇺🇸 United States31.5%
🏳️ Korea23.1%
🏳️ Republic of8.5%
🇮🇩 Indonesia6.2%
🇯🇵 Japan6.2%
Top 5 markets shown

Talent graph

The shape of Element Biosciences's talent

Dealroom maps Element Biosciences's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

9 standout operatorsDealroom-flagged across the org
3 AI specialistsincl. 2 core researchers
447 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Element Biosciences's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Element Biosciences

An AI-synthesized read of the highest-engagement posts about Element Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Element Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.